留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

应中央军委要求,2022年9月起,《药学实践杂志》将更名为《药学实践与服务》,双月刊,正文96页;2023年1月起,拟出版月刊,正文64页,数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿!

7种新型口服抗凝药预防全髋、膝关节置换术后静脉血栓栓塞症的网状Meta分析

杨婕 温华 马冰 孙晶

杨婕, 温华, 马冰, 孙晶. 7种新型口服抗凝药预防全髋、膝关节置换术后静脉血栓栓塞症的网状Meta分析[J]. 药学实践与服务, 2018, 36(6): 541-546. doi: 10.3969/j.issn.1006-0111.2018.06.014
引用本文: 杨婕, 温华, 马冰, 孙晶. 7种新型口服抗凝药预防全髋、膝关节置换术后静脉血栓栓塞症的网状Meta分析[J]. 药学实践与服务, 2018, 36(6): 541-546. doi: 10.3969/j.issn.1006-0111.2018.06.014
YANG Jie, WEN Hua, MA Bing, SUN Jing. Seven kinds of new oral anticoagulants for prevention of venous thromboembolism after total hip or knee arthroplasty: a net Meta-analysis[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(6): 541-546. doi: 10.3969/j.issn.1006-0111.2018.06.014
Citation: YANG Jie, WEN Hua, MA Bing, SUN Jing. Seven kinds of new oral anticoagulants for prevention of venous thromboembolism after total hip or knee arthroplasty: a net Meta-analysis[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(6): 541-546. doi: 10.3969/j.issn.1006-0111.2018.06.014

7种新型口服抗凝药预防全髋、膝关节置换术后静脉血栓栓塞症的网状Meta分析

doi: 10.3969/j.issn.1006-0111.2018.06.014

Seven kinds of new oral anticoagulants for prevention of venous thromboembolism after total hip or knee arthroplasty: a net Meta-analysis

  • 摘要: 目的 采用网状Meta分析法,比较7种新型口服抗凝药预防全髋、膝关节置换术后静脉血栓栓塞症作用的有效性。 方法 检索CBM、Cochrane Library、Pubmed等数据库,从中提取随机对照试验,进行质量评价。应用软件Stata12.0,采用mvmeta程序包分析数据。 结果 检索相关文献1 091篇,24篇符合标准,共计40 001例患者;按处方药物用量评价预防静脉血栓栓塞症的有效性。直接比较结果:利伐沙班、阿哌沙班优于低分子肝素,结果分别为:RR=0.56,95% CI:0.40~0.78,P<0.05;RR=0.39,95% CI:0.24~0.63,P<0.05。其余5种新型口服抗凝药与低分子肝素比较无显著差别(P>0.05)。间接比较,结果均优于安慰剂。 结论 7种新型口服抗凝药预防全髋、膝关节置换术后静脉血栓栓塞症的有效性等级排名:阿哌沙班最佳,其次为利伐沙班、依度沙班、Ym150、TAK-442、达比加群酯、贝曲沙班。
  • [1] 吴丹辰,贾镭,徐希奇,等.新型口服抗凝药物预防及治疗静脉血栓栓塞症研究进展[J].中华关节外科杂志[J/OL],2013,7(3):420.
    [2] 邱贵兴.中国骨科大手术静脉血栓栓塞症预防指南[J].中华关节外科杂志[J/OL],2009,3(3):380.
    [3] 张超,陶华,李胜,等.应用Stata软件mvmeta程序包实现网状Meta分析[J].Chin J Evid-based Med,2014,14(9):1150-1159.
    [4] ERIKSSON B,DNHL OE,ROSENEHER N,et al.Dabigatran etexilate for prevention of venous thromboembolism after total hip replacement a randomised double-blin non-inferiority trial[J].Lancet,2007,370(9591):949-956.
    [5] ERIKSSON BI,DAHL OE,HUO MH,et al.Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty[J].Thromb Haemost,2011,105(4):721-729.
    [6] ERIKSSON B,DNHL OE,ROEENCHER N,et al.Oral dabigatran etexilate and subctltalleous enoxparin for the prevention of veneous thromboembolism after total knee replacement the RE-MODEL randomized trial[J].J Thromb Haemost,2007,5(11):2178-2185.
    [7] GINSBERG JS,DAVIDSON BL,COMP PC,et al.Oral thrombin inhibitor or dabigatan etexilate and North Ameriean enoxaparin regimen for prevention of venous thrombomembolism after knee arthroplasty surgery[J].J Arthroplasty,2009,24(1):1-9.
    [8] ERIKSSON BI,BORRIS LC,FRIEDMAN RJ,et al.Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty[J].N Engl J Med,2008,358(26):2765-2775.
    [9] KAKKAR AK,BRENNER B,DAHL OE,et al.Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty:a double-blind,randomised controlled trial[J].Lancet,2008,372(9632):31-39.
    [10] LASSEN MR,AGENO W,BORRIS LC,et al.Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty[J].N Engl J Med,2008,358(26):2776-2786.
    [11] TURPIE AG,LASSEN MR,DAVIDSON BL,et al.Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4) a randomised trial[J].Lancet,2009,373(9676):1673-1680.
    [12] ERIKSSON BI,BORRIS L,DAHL OE,et al.For the ODIXa-HIP investigators study a randomised trial:a once-daily oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939) for thromboprophylaxis after total hip replacement[J]. Circulation,2006,114(22):2374-2381.
    [13] ERIKSSON BI,BORRIS L,DAHL OE,et al.For the ODIXa-HIP investigators study a randomised trial:oral direct factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement[J]. Thromb Haemost,2006,4:121-128.
    [14] TURPIE, FISHER, BAUER,et al.BAY 59-7939 an oral direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement a phase Ⅱ dose-ranging study[J].Thromb Haemost,2005,3(11):2479-2486.
    [15] ERIKSSON BI,BORRIS LC,DAHL OE,et al.Dose-escalation study of rivaroxaban(BAY 59-7939) an oral direct factor Xa inhibitor-for the prevention of venous thromboembolism in patients undergoing total hip replacement[J].Thromb Res,2007,120(5):685-693.
    [16] LASSEN MR,DAVIDSON BL,GALLUS A,et al.The efficacy and safety of apixaban an oral direct factor Xa inhibitor as thromboprophylaxis in patients following total knee replacement[J].J Thromb Haemost,2007,5(12):2368-2375.
    [17] LASSEN MR,RASKOB GE,GALLUS A,et al.Apixaban or enoxaparin for thromboprophylaxis after knee replacement[J].N Engl J Med,2009,361(6):594-604.
    [18] LASSEN MR,RASKOB GE,GALLUS A,et al.Apixaban versus enoxaparin for thromboprophylaxis after knee replacement a randomised double-blind trial[J].Lancet,2010,375(9717):807-815.
    [19] LASSEN MR,GALLUS A,RASKOB GE,et al.Apixaban versus enoxaparin for thromboprophylaxis after hip replacement[J].N Engl J Med,2010,363(26):2487-2498.
    [20] FUJI T,FUJITA S,TACHIBANA S,et al.A dose-ranging study evaluating the oral factor Ⅹa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty[J].J Thromb Haemost,2010,8(11):2458-2468.
    [21] FUJI T,FUJITA S,KAWAI Y,et al.Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty:STARS J-V[J].Thromb J,2015,13:27.
    [22] RASKOB G,COHEN AT,ERIKSSON BI,et al.Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement.a randomised double-blind dose-response study[J].Thromb Haemost,2010,104(3):642-649.
    [23] TURPIE AG,BAUER KA,DAVIDSON BL,et al. A randomized evaluation of betrixaban an oral factor Xa inhibitor for prevention of thromboembolic events after total knee replacement[J].Thromb Haemost,2009,101(1):68-76.
    [24] WEITZ JI,CAO C,ERIKSSON BI,et al.A dose-finding study with TAK-442 an oral factor Xa inhibitor in patients undergoing elective total knee replacement surgery[J].Thromb Haemost,2010,104(6):1150-1157.
    [25] ERIKSSON BI,TURPIE AG,LASSEN MR,et al.Prevention of venous thromboembolism with an oral factor Xa inhibitor YM150 after total hip arthroplasty a dose finding study (ONYX-2)[J].Journal of Thrombosis and Haemostasis,2010,8:714-721.
    [26] FUJI T,NAKAMURA M,TAKEUCHI M.Darexaban for the prevention of venous thromboembolism in Asian patients undergoing orthopedic surgery results from 2 randomized placebo-controlled,double-blind studies[J].Clinical and Applied Thrombosis Hemostasis,2014,20(2):199-211.
    [27] ERIKSSON BI,AGNELLI G,GALLUS AS,et al.Darexaban (YM150) versus enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty a randomised phase Ⅱb dose confirmation study (ONYX-3)[J].Thromb Haemost,2014,111(2):213-225.
    [28] STEVENSON M,SCOPE A,HOLMES M,et al.Rivaroxaban for the prevention of venous thromboembolism a single technology appraisal[J].Health Technol Assess,2009,13:43-48.
    [29] GOMEZ-OUTESA,TERLEIRA-FERNANDEZ AI,SUAREZ-GEA ML,et al.Dabigatran rivaroxaban or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement systematic review meta-analysis,and indirect treatment comparisons[J].BMJ,2012,344(14):3675.
  • [1] 陈乾, 徐向阳, 陆方林, 韩林, 李白翎, 徐志云.  体外循环下三尖瓣置换术后患者预防性使用胃肠动力药的疗效观察 . 药学实践与服务, 2024, 42(3): 131-134. doi: 10.12206/j.issn.2097-2024.202210060
    [2] 董发慧, 韩金刚.  地塞米松联合右美托咪定对罗哌卡因股神经阻滞用于老年患者全膝关节置换术后镇痛效果的评价 . 药学实践与服务, 2023, 41(2): 125-129. doi: 10.12206/j.issn.2097-2024.202109020
    [3] 屈茹楠, 毛峻琴, 信如娟, 张贺, 高岸.  1例化脓性血栓静脉炎继发肺部感染患者的药物治疗分析 . 药学实践与服务, 2022, 40(2): 171-174. doi: 10.12206/j.issn.1006-0111.202107045
    [4] 赖彦岚, 黄爱文, 陈官旭, 陈婷婷, 赵丽君, 廖小兰, 郭秀强, 吴刚, 宋洪涛.  SGLT-2抑制剂及GLP-1受体激动剂治疗2型糖尿病的心血管获益:一项系统回顾和网状Meta分析 . 药学实践与服务, 2022, 40(4): 354-358. doi: 10.12206/j.issn.1006-0111.202109108
    [5] 蓝晓红, 徐建新, 周永刚.  1例雌二醇/雌二醇地屈孕酮致下肢静脉血栓及危险因素分析 . 药学实践与服务, 2021, 39(2): 191-192. doi: 10.12206/j.issn.1006-0111.202009086
    [6] 平伟, 王伟, 宋巍, 李盼红, 刘小娟.  氨甲环酸在全膝关节置换术围术期的应用效果分析 . 药学实践与服务, 2021, 39(4): 362-365. doi: 10.12206/j.issn.1006-0111.202102020
    [7] 孙斌, 王子婧, 曹阳, 孟蕊, 杨岚, 朱金宝.  非甾体抗炎药治疗我国中老年骨关节炎疗效和安全性的网状Meta分析 . 药学实践与服务, 2021, 39(3): 259-266. doi: 10.12206/j.issn.1006-0111.202101022
    [8] 费舒扬, 赵力, 孙琳, 张蓉, 李晶, 葛长江.  植入药物洗脱支架后短期与长期双联抗血小板疗效比较的Meta分析 . 药学实践与服务, 2020, 38(1): 81-87. doi: 10.3969/j.issn.1006-0111.201907135
    [9] 杨贤, 郑萍.  临床药师参与1例亚急性心肌梗死合并腔隙性脑梗及深静脉血栓患者的抗栓治疗体会 . 药学实践与服务, 2017, 35(2): 161-164. doi: 10.3969/j.issn.1006-0111.2017.02.016
    [10] 马宗强, 安洪亮.  门诊口服抗高血压药物的调查分析 . 药学实践与服务, 2016, 34(2): 188-190,192. doi: 10.3969/j.issn.1006-0111.2016.02.024
    [11] 张强, 李健, 彭冉, 黎永娴.  甲状腺手术围术期抗溃疡药使用分析 . 药学实践与服务, 2016, 34(3): 271-274. doi: 10.3969/j.issn.1006-0111.2016.03.020
    [12] 崔丽, 刘俊.  药物基因组学模型对机械瓣膜置换术后华法林低强度抗凝治疗剂量预测效果的评价 . 药学实践与服务, 2016, 34(3): 241-244,270. doi: 10.3969/j.issn.1006-0111.2016.03.012
    [13] 钱皎, 王卓, 曹爱霖.  1例胺碘酮致华法林抗凝作用增强病例分析 . 药学实践与服务, 2015, 33(6): 566-569. doi: 10.3969/j.issn.1006-0111.2015.06.023
    [14] 张榕红, 王红.  膝关节骨性关节炎应用中药熏洗疗法 . 药学实践与服务, 2001, (6): 329-329.
    [15] 董亲颐.  一类新型抗高血压药-AⅡ受体拮抗剂 . 药学实践与服务, 1998, (1): 28-33.
    [16] 董崴, 姜远英.  新型抗痴呆药──Nefiracetam的研究进展 . 药学实践与服务, 1996, (3): 137-138.
    [17] 吕惠春, 彭学贤, 陈明捷.  自拟玄花汤治疗深部静脉血栓病15例疗效观察 . 药学实践与服务, 1996, (3): 141-142.
    [18] 王毅翔, 刘子江, 陆文光.  顺铂苯乙烯微囊经门静脉化疗栓塞的实验研究 . 药学实践与服务, 1992, (3): 2-4.
    [19] 洪中立, 曲静伟.  新型抗高血压药乌拉地尔的临床应用 . 药学实践与服务, 1992, (4): 6-7.
    [20] 孟庆棣, 陈育尧.  新抗凝临床剂量的实验研究 . 药学实践与服务, 1988, (3): 17-19.
  • 加载中
计量
  • 文章访问数:  2679
  • HTML全文浏览量:  382
  • PDF下载量:  402
  • 被引次数: 0
出版历程
  • 收稿日期:  2017-12-01
  • 修回日期:  2018-08-25

7种新型口服抗凝药预防全髋、膝关节置换术后静脉血栓栓塞症的网状Meta分析

doi: 10.3969/j.issn.1006-0111.2018.06.014

摘要: 目的 采用网状Meta分析法,比较7种新型口服抗凝药预防全髋、膝关节置换术后静脉血栓栓塞症作用的有效性。 方法 检索CBM、Cochrane Library、Pubmed等数据库,从中提取随机对照试验,进行质量评价。应用软件Stata12.0,采用mvmeta程序包分析数据。 结果 检索相关文献1 091篇,24篇符合标准,共计40 001例患者;按处方药物用量评价预防静脉血栓栓塞症的有效性。直接比较结果:利伐沙班、阿哌沙班优于低分子肝素,结果分别为:RR=0.56,95% CI:0.40~0.78,P<0.05;RR=0.39,95% CI:0.24~0.63,P<0.05。其余5种新型口服抗凝药与低分子肝素比较无显著差别(P>0.05)。间接比较,结果均优于安慰剂。 结论 7种新型口服抗凝药预防全髋、膝关节置换术后静脉血栓栓塞症的有效性等级排名:阿哌沙班最佳,其次为利伐沙班、依度沙班、Ym150、TAK-442、达比加群酯、贝曲沙班。

English Abstract

杨婕, 温华, 马冰, 孙晶. 7种新型口服抗凝药预防全髋、膝关节置换术后静脉血栓栓塞症的网状Meta分析[J]. 药学实践与服务, 2018, 36(6): 541-546. doi: 10.3969/j.issn.1006-0111.2018.06.014
引用本文: 杨婕, 温华, 马冰, 孙晶. 7种新型口服抗凝药预防全髋、膝关节置换术后静脉血栓栓塞症的网状Meta分析[J]. 药学实践与服务, 2018, 36(6): 541-546. doi: 10.3969/j.issn.1006-0111.2018.06.014
YANG Jie, WEN Hua, MA Bing, SUN Jing. Seven kinds of new oral anticoagulants for prevention of venous thromboembolism after total hip or knee arthroplasty: a net Meta-analysis[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(6): 541-546. doi: 10.3969/j.issn.1006-0111.2018.06.014
Citation: YANG Jie, WEN Hua, MA Bing, SUN Jing. Seven kinds of new oral anticoagulants for prevention of venous thromboembolism after total hip or knee arthroplasty: a net Meta-analysis[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(6): 541-546. doi: 10.3969/j.issn.1006-0111.2018.06.014
参考文献 (29)

目录

    /

    返回文章
    返回